Document is current
Any future updates will be listed below
-
Authors
Bril, Vera https://orcid.org/0000-0002-5805-4883
Drużdż, Artur
Grosskreutz, Julian
Habib, Ali A.
Kaminski, Henry J.
Mantegazza, Renato
Sacconi, Sabrina
Utsugisawa, Kimiaki
Vu, Tuan
Boehnlein, Marion
Gayfieva, Maryam
Greve, Bernhard
Woltering, Franz
Vissing, John
,
Álvarez-Velasco, Rodrigo
Aly, Radwa
Andersen, Henning
Antonini, Giovanni
Balogun, Aramide
Barnabei, Ruggero
Beydoun, Said
Blaes, Franz
Bonarino, Silvia
Soevang, Anna Boss
Botchorishvili, Nazibrola
Botez, Stephan A.
Bozovic, Ivo
Budzinska, Paulina
Businaro, Pietro
Campetella, Lucia
Cánovas, Ana Belen
Casasnovas, Carlos
Chiu, Hou-Chang
Chou, His-Chieh
Comer, Adam
Vicente, Elena Cortés
D’Angelo, Roberto
Daniyal, Lubna
Dionne, Annie
Diószeghy, Péter
Fionda, Laura
Flemm, Denis
Frangiamore, Rita
Gambella, Manuela
Mehta, Rachana K. Gandhi
Garibaldi, Matteo
Gastaldi, Matteo
Geis, Christian
George, Hannah
Gingele, Stefan
Martin, Monica Grau
Guo, Yuh-Cherng
Gutiérrez Gutiérrez, Gerardo
Habetswallner, Francesco
Hassoun, Lina
Holm-Yildiz, Sonja
Hussain, Faraz
Iniesta, Francisca
Irodenko, Viktoriya
Janelidze, Marina
Kang, Min
Karam, Chafic
Korobko, Denis
Kotov, Sergey
Kretkowski, Michal
Kvirkvelia, Nana
Lauletta, Antonio
Lee, Yi-Chung
Leonardi, Luca
Liow, Kore
Gayete, Arnau Llauradó
Llufriu, Sara
Lomen-Hoerth, Catherine
Lünemann, Jan D.
Maggi, Lorenzo
Hernández, Eugenia Martínez
Masi, Gianvito
Masingue, Marion
Massie, Rami
Masullo, Marco
Mazzacane, Federico
Möhn, Nora
Morino, Stefania
Moulton, Kelsey
Mozaffar, Tahseen
Nebadze, Elene
Nedkova-Hristova, Velina
Ng, Eduardo
Novikova, Ekaterina
Obál, Izabella
Palsgård, Anita
Papi, Claudia
Pérez, Lorena
Peric, Stojan
Petrov, Mikhail
Preisler, Nicolai Rasmus
Querin, Giorgia
Rejdak, Konrad
Rezania, Kourosh
Rinaldi, Elena
Rinaldi, Rita
Rivner, Michael H.
Roediger, Annekathrin
Rosow, Laura
Rossi, Simone
Rossini, Elena
Ryan, Stephen
Levison, Lotte Sahin
Saiz, Albert
Salvado, Maria
Sánchez-Tejerina, Daniel
Schwarz, Margret
Sepúlveda, María
Sharma, Khema R.
Shroff, Sheetal
Sidorova, Olga
Solé, Guilhem
Sotoca, Javier
Stemmerik, Mads
Stojanov, Aleksandar
Stojkovic, Tanya
Su, Kai
Szklener, Sebastian
Tsiskaridze, Alexander
Tufano, Laura
Tyblova, Michaela
Uenaka, Eiko
Unterlauft, Astrid
Valero, Gabriel
Vanoli, Fiammetta
Vashadze, Tamar
Fernández, Nuria Vidal
Violleau, Marie-Hélène
Weiss, Nicolas
Witting, Nanna
Yeh, Jiann-Horng
Zaidi, Leila
Zaslavskiy, Leonid
Zschüntzsch, Jana
-
Funding
Funding for this research was provided by:
UCB
- License Information
-
More Information
Article History
Received: 1 November 2024
Revised: 30 January 2025
Accepted: 1 February 2025
First Online: 19 March 2025
Declarations
:
: The study protocol, amendments, and study participant informed consent were approved by a national, regional or independent ethics committee or institutional review board. All patients provided written informed consent. The study was conducted in accordance with local regulations, the International Conference on Harmonization Good Clinical Practice requirements, and the principles of the Declaration of Helsinki.
: V. Bril is a Consultant for Akcea, Alexion Pharmaceuticals, Alnylam, argenx, CSL, Grifols, Immunovant, Ionis, Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine), Momenta (now Johnson & Johnson), Novo Nordisk, Octapharma, Pfizer, Powell Mansfield, Roche, Sanofi, Takeda Pharmaceuticals and UCB. She has received research support from Akcea, Alexion Pharmaceuticals, argenx, CSL, Grifols, Immunovant, Ionis, Momenta (now Johnson & Johnson), Octapharma, Takeda Pharmaceuticals, UCB and Viela Bio (now Amgen). A. Drużdż has nothing to disclose. J. Grosskreutz has served as a Consultant for Alexion Pharmaceuticals, Biogen and UCB, and his institution has received research support from the Boris Canessa Foundation. A.A. Habib has received research support from Alexion Pharmaceuticals, argenx, Cabaletta Bio, Genentech/Roche, Immunovant, Regeneron Pharmaceuticals, UCB and Viela Bio (now Amgen). He has received honoraria from Alexion Pharmaceuticals, Alpine Immune Sciences, argenx, Genentech/Roche, Immunovant, Inhibrx, NMD Pharma, Regeneron Pharmaceuticals and UCB. H.J. Kaminski is a Consultant for Cabaletta Bio, Lincoln Therapeutics, Roche, Takeda Pharmaceuticals and UCB, and is CEO and CMO of ARC Biotechnology, LLC based on US Patent 8,961,98. He is Principal Investigator of the Rare Disease Network for Myasthenia Gravis (MGNet) National Institute of Neurological Disorders & Stroke, U54 NS115054, and Targeted Therapy for Myasthenia Gravis. He has received R41 NS110331-01 to ARC Biotechnology. R. Mantegazza has received funding for travel and meeting attendance or advisory board participation from Alexion Pharmaceuticals, argenx, BioMarin, Catalyst, Sanofi, Regeneron Pharmaceuticals Sanofi and UCB. S. Sacconi has nothing to disclose. K. Utsugisawa has served as a paid Consultant for argenx, Chugai Pharmaceutical, HanAll Biopharma, Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine), Merck, Mitsubishi Tanabe Pharma, UCB and Viela Bio (now Amgen); he has received speaker honoraria from Alexion Pharmaceuticals, argenx, the Japan Blood Products Organization and UCB. T. Vu is the USF Site Principal Investigator for MG clinical trials sponsored by Alexion/AstraZeneca Rare Disease, Amgen, argenx, Cartesian Therapeutics, COUR Pharmaceuticals, Dianthus Therapeutics, Immunovant, Johnson & Johnson, NMD Pharma, Regeneron Pharmaceuticals and UCB, and has served as a speaker for Alexion/AstraZeneca Rare Disease, argenx and CSL Behring. He performed consulting work for Alexion/AstraZeneca Rare Disease, argenx, Dianthus Therapeutics, ImmunAbs and UCB. M. Boehnlein is an employee and shareholder of UCB. M. Gayfieva is a former employee and shareholder of UCB. B. Greve is an employee and shareholder of UCB. F. Woltering is an employee and shareholder of UCB. J. Vissing has been a Consultant on advisory boards for Amicus Therapeutics, Biogen, Edgewise Therapeutics, Fulcrum Therapeutics, Genethon, Horizon Therapeutics (now Amgen), Lupin, ML Biopharma, Novartis, Regeneron Pharmaceuticals, Roche, Sanofi Genzyme (now Sanofi), Sarepta Therapeutics and UCB. He has received research, travel support and/or speaker honoraria from Alexion Pharmaceuticals, argenx, Biogen, Edgewise Therapeutics, Fulcrum Therapeutics, Lupin, Sanofi Genzyme (now Sanofi) and UCB. He is a Principal Investigator in clinical trials for Alexion Pharmaceuticals, argenx, Atamyo Therapeutics, Genethon, Horizon Therapeutics (now Amgen), Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine), ML Biopharma, Novartis, Regeneron Pharmaceuticals, Roche, Sanofi Genzyme (now Sanofi) and UCB.
